Today: October 17, 2017, 12:19 am
  
Health

New Market Report: Single-cell Analysis Market - Global Forecasts to 2022

New Biotechnology market report from Markets and Markets: "Single-cell Analysis Market - Global Forecasts to 2022"
New Market Report: Single-cell Analysis Market - Global Forecasts to 2022
PR-Inside.com: 2017-07-17 15:25:21
Single-cell Analysis Market by Product (Consumables and Instruments), Cell Type (Human and Animal), Technique (Flow Cytometry, NGS, PCR, and Mass Spectrometry), Application (Cancer, Neurology, NIPD, IVF, and CTCs), End User - Global Forecasts to 2022

"Single-cell analysis market projected to register a CAGR of 16.5%"

The single-cell analysis market is expected to reach USD 3.59 billion by 2022 from USD 1.67 billion in 2017, at a CAGR of 16.5%. Technological advancements in single-cell analysis products, increasing government funding for cell-based research, growing biotechnology and biopharmaceutical industries, wide applications of single-cell analysis in cancer research, growing focus on personalized medicine, and increasing incidence and prevalence of chronic and infectious diseases are driving the growth of the single-cell analysis market. On the other hand, the high cost of single-cell analysis instruments may hinder the growth of the market in the coming years.


Full Report Details at
- www.fastmr.com/prod/1293322_single_cell_global_forecasts.aspx?af ..

"Consumables segment are expected to witness high growth during forecast period"

Based on product, the single-cell analysis market is segmented into consumables and instruments. Consumables are expected to register the highest CAGR during the forecast period. Consumables are further segmented into beads, microplates, reagents, assay kits, and other consumables, whereas, instruments are further segmented into flow cytometers, NGS systems, PCR instruments, HCS systems, microscopes, cell counters, spectrophotometers, cell microarrays, and other instruments. Players from the market are increasingly focusing on technological advancements and product development to launch efficient cytometry instruments which is driving the growth of the segment.

"Human cells to dominate the single-cell analysis market"

Based on the type of cells, the single-cell analysis market is segmented into human, animal, and microbial cells. The human cells segment is expected to dominate this market with the largest share in 2017. The large share of this segment can be attributed to the growing application areas of human stem cells and rising incidence of diseases such as cancer.

"NGS to account with the highest growth rate in the single-cell analysis market"

Based on technique, the single-cell analysis market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques (including single-molecule fluorescence in situ hybridization, micromanipulation, and automated capillary electrophoresis). NGS segment is projected to grow at the highest rate during the forecast period.

"North America to dominate the market during forecast period"

In 2017, North America is expected to account for the largest share of the single-cell analysis market. Factors such as increasing collaborations among prominent players, technological advancements and expanding biotechnology and pharmaceutical industries are supporting the growth of the single-cell analysis market in this region. Asian region is expected to register the highest CAGR during the forecast period. The large population in China and India, rising geriatric population, and increasing incidence of chronic diseases are the major factors driving the growth of the Asian market.

The primary interviews conducted for this report can be categorized as follows:

* By Company Type: Tier 1 - 35%; Tier 2, 40%; Tier 3, 25%.
* By Designation: C- level- 35%; D-level- 25%; others- 40%.
* By Region: North America - 43%; Europe- 19%; Asia- 29%; and Rest of the World (RoW) - 9%

*Note: Others include sales managers, marketing managers, and product managers

Tiers of the companies are defined by their total revenue. As of 2016: Tier 1 = >USD 1 billion, Tier 2 = USD 100 million to USD 1 billion, and Tier 3 =< USD 100 million

List of Companies Benchmarked in the report

* Merck KGaA (Germany)
* Becton, Dickinson and Company (U.S.)
* Promega Corporation (U.S.)
* Danaher Corporation (U.S.)
* General Electric Company (U.K.)
* Thermo Fisher Scientific Inc. (U.S.)
* Miltenyi Biotec (Germany)
* Illumina, Inc. (U.S.)
* Bio-Rad Laboratories, Inc.(U.S.)
* Fluidigm Corporation (U.S.)
* NanoString Technologies, Inc. (U.S.)
* Agilent Technologies (U.S.)
* Abcam Plc (U.S.)
* NuGEN Technologies Inc.(U.S.)
* LumaCyte (U.S.)
* PluriSelect Life Science UG & Co. KG (Germany)
* Sysmex Partec (U.S.)
* Bio-Techne Corporation (U.S.)
* Promega Corporation (U.S.)
* 10x Genomics (U.S.)
* WaferGen Bio-systems, Inc. (U.S.)
* Bruker (U.S.)
* Fluxion Biosciences (U.S.).

Research Coverage:

About MarketsandMarkets

MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. The company publishes high-level strategically analyzed reports for over ten industry verticals and serves as a business intelligence partner to Fortune 500 companies across the world. View more research from Markets and Markets at www.fastmr.com/catalog/publishers.aspx?pubid=1014&afid=701

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

Press Information


Published by
Bill Thompson
18008448156
e-mail
www.fastmr.com



# 818 Words
Related Articles
More From The Author
New Study: Non Alcoholic Fatty Liver Disease [..]
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 20 Summary Global Markets Direct's latest Pharmaceutical and [..]
New Study: Primary Biliary Cirrhosis - Pipeline [..]
Primary Biliary Cirrhosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease [..]
Electricity and Power (Construction) in Singapore: Market [..]
The electricity and power category covers construction activities related to power generation and transmission and include buildings [..]
Residential Construction Market in Australia: Market Size, [..]
Residential construction market covers new construction, renovation and demolition of residential buildings such as houses, townhouses, [..]
Now Available: Shotcrete Accelerator Market - Global [..]
Shotcrete Accelerator Market by Type (Alkali Free, Alkaline Aluminate, Alkaline Silicate), Grade (Liquid, Powdered), Process (Wet [..]
 
More From Health
“Reverse Abscopal Effect” in Rheumatoid Arthritis Using [..]
Biotech Holdings Announces Effective Induction of “Reverse Abscopal Effect” in Rheumatoid Arthritis Using Procell Activated Stem [..]
Air Optix Aqua Contacts from Alcon Keeps [..]
Alcon Laboratories’ Air Optix Aqua 6 pack contact lenses bring together two advanced technologies designed to provide long-lasting [..]
Simple Biomechanical Test could aid Implant Success
Tsukuba, Japan, Oct 10, 2017 - (ACN Newswire) - The quality of the tissue-implant interface is key to the success [..]
Daily Disposable Wear from Sauflon Clariti Keeps [..]
Sauflon Clariti is designed to give customers daily disposable lenses with the benefits of silicone hydrogel material and AquaGen [..]
Understanding Prescription Opioid Addiction, Riverside Clinic [..]
A recent report on ABC News says over the past decade the use of opioid-based prescription painkillers has quadrupled. Over [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.